This $14.8 million contract award to Seqirus Inc., a subsidiary of CSL Limited ($CSL), for medical countermeasures significantly boosts CSL's role in pandemic preparedness, representing a meaningful revenue addition and reinforcing its market position in vaccine development.
Impact: 6/10Federal Contract